Breaking the PMA Bottleneck: How FDA's Class II Reclassification Accelerates Precision Oncology
Dr. Dereck Mush, MD, MBA
Kheiron Medical Technologies
Deploys deep learning to assist radiologists in detecting early-stage breast cancer.
What they do
Kheiron Medical Technologies develops Mia, an artificial intelligence platform designed to support radiologists in breast cancer screening. The software analyzes digital mammograms to act as an independent second reader, improving early detection rates while reducing workloads for clinical imaging teams.
The record
- Vertical
- Oncology
- Sub-segment
- AI-powered radiology diagnostics
- Product type
- Software as a medical device
- Stage
- Series A
- Headquarters
- London, United Kingdom
- Region
- Europe
- Founded
- 2016
- Total funding
- $22M raised
Notable investors: Atomico, Greycroft, Connect Ventures, Hoxton Ventures.
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
Does AI Actually Improve Radiology Accuracy? What the Prospective Trials Show in 2026
Dr. Dereck Mush, MD, MBA
The Radiopharmaceutical Infrastructure Playbook: Why Telix's FDA Approval for Pixclara Redefines Neuro-Oncology Diagnostics and Theranostics
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Full body MRI is the fastest growing product in longevity medicine. The evidence has not caught up
Full body MRI is the fastest growing product in longevity medicine. The evidence has not caught up
Dr. Dereck Mush, MD, MBA